Watch ATOS. Know when insiders buy.
One email the day a filing lands. Free.
ATOS
ATOSSA THERAPEUTICS, INC.
2.52
−0.01 −0.40%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
39
FLAG · shorts 39
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $25.1MP/E —DIV YIELD —FCF YIELD -142.29%REV TTM —NET INCOME −$37.7MNET CASH $26.1M52W 1.75 – 17.70SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$8.7M | −$8.5M | — | -0.95 | −$9.6M | $0 | −$9.6M | Aug 7 |
| Q1 2026 · Mar 31 | — | — | — | −$9.9M | −$9.6M | — | -1.11 | −$9.6M | $0 | −$9.6M | Aug 7 |
| Q4 2025 · Dec 31derived | — | — | — | −$11.4M | −$10.9M | — | -3.86 | −$10.5M | $7K | −$10.5M | Mar 25 |
| Q3 2025 · Sep 30 | — | — | — | −$9.3M | −$8.7M | — | -0.07 | −$6M | $7K | −$6M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$9M | −$8.4M | — | -0.98 | −$7.3M | $0 | −$7.3M | Aug 7 |
| Q1 2025 · Mar 31 | — | — | — | −$7.4M | −$6.7M | — | -0.78 | −$6M | $9K | −$6M | Aug 7 |
| Q4 2024 · Dec 31derived | — | — | — | −$7.2M | −$6.3M | — | -2.89 | −$7.1M | $0 | −$7.1M | Mar 25 |
| Q3 2024 · Sep 30 | — | — | — | −$6.4M | −$7.2M | — | -0.06 | −$4.8M | $10K | −$4.8M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$7.1M | −$6M | — | -0.05 | −$4.5M | $3K | −$4.5M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$7M | −$5.9M | — | -0.05 | −$4.7M | $6K | −$4.7M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$9M | −$7.8M | — | -0.06 | −$5.6M | $0 | −$5.6M | Mar 25 |
| Q3 2023 · Sep 30 | — | — | — | −$7.5M | −$6.2M | — | -0.05 | −$3.9M | $1K | −$3.9M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$37.1M | −$34.8M | — | -4.04 | −$29.8M | $23K | −$29.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$27.6M | −$25.5M | — | -3.04 | −$21M | $19K | −$21M | $0 | — |
| FY2023 · to Dec 31 | — | — | −$31.4M | −$30.1M | — | -0.24 | −$20.9M | $14K | −$21M | $1.5M | — |
| FY2022 · to Dec 31 | — | — | −$27.7M | −$27M | — | -0.21 | −$20.8M | $27K | −$20.8M | $0 | — |
| FY2021 · to Dec 31 | — | — | −$20.5M | −$20.6M | — | -0.18 | −$16.5M | $9K | −$16.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$14.6M | −$17.8M | — | -1.97 | −$11.6M | $9K | −$11.6M | — | — |
Every number comes from ATOSSA THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.